GLP-1s, PCOS, and trying to conceive: what the evidence says

What's this video probably claiming?

Based on the caption and hashtag cluster, this creator is sharing her personal experience starting a GLP-1 receptor agonist, likely semaglutide or tirzepatide, while managing PCOS, prediabetes, and actively trying to conceive. The #ttc and #infertility tags alongside #glp1forweightloss suggest she's framing GLP-1 therapy as potentially supportive of her fertility goals, probably through weight loss and improved insulin sensitivity. She's likely claiming, or implying, that losing weight on a GLP-1 while in a calorie deficit can help regulate cycles and improve chances of conception in people with PCOS. She may also be positioning these drugs as broadly safe for people in her situation. The community-sourcing framing, asking followers for tips, signals this is experiential advice rather than clinical guidance. That distinction matters a lot when pregnancy is in the picture.

What does the science actually show?

The metabolic case for GLP-1 use in PCOS is real, but it's not the fertility green light social media makes it sound like. A 2023 meta-analysis in Reproductive BioMedicine Online (Elkind-Hirsch et al.) found that GLP-1 receptor agonists improved menstrual regularity and reduced androgen levels in women with PCOS, largely through weight loss and reduced insulin resistance. A separate 2022 RCT in Diabetes Care showed semaglutide 1.0 mg weekly reduced HbA1c and body weight significantly in prediabetic adults over 68 weeks. For PCOS specifically, a 2021 study in Frontiers in Endocrinology noted that even 5-10% body weight reduction can restore ovulation in anovulatory PCOS. So the metabolic rationale is solid. What is not solid: direct evidence that GLP-1s improve live birth rates, or that they are safe to continue once pregnancy is confirmed. These are two very different things.

Where does the social media noise diverge from clinical reality?

Here's the part that keeps reproductive endocrinologists up at night. GLP-1 receptor agonists are classified as pregnancy category X by most prescribers, meaning they should be discontinued before attempting conception, generally at least two months before trying, based on half-life and animal study data showing fetal harm at high doses. The FDA label for semaglutide explicitly advises discontinuation at least two months prior to planned pregnancy. That warning is conspicuously absent from most TikTok GLP-1 content. Additionally, the #caloriedeficit hashtag alongside #ttc raises another flag: aggressive caloric restriction during the conception window can suppress LH pulsatility and impair implantation. Using a GLP-1, which blunts appetite significantly, while also intentionally restricting calories requires careful medical supervision, especially when trying to conceive. The casual community-tips framing undersells that complexity.

What should you actually know?

If you have PCOS, prediabetes, and are trying to conceive, GLP-1 therapy may genuinely help your metabolic picture before pregnancy, but the timing and transition off the medication needs to be managed by a reproductive endocrinologist or OB-GYN with metabolic experience, not a TikTok comment section. The American Society for Reproductive Medicine does not currently endorse GLP-1s as a fertility treatment. Weight loss through any mechanism can improve ovulation in PCOS, but that doesn't make GLP-1s a TTC tool. The calorie deficit piece also needs supervision: restrictive eating patterns can worsen hormonal function in women already dealing with HPA axis dysregulation from PCOS. None of this means the creator is wrong to share her journey. It means her experience is one data point, not a protocol. Talk to your prescriber before combining these approaches near a planned pregnancy.